SCHEMBL2195565

SCHEMBL2195565

Cc1cn(C2CCCCC2)c(=[Pt])n1C1CCCCC1.IN(I)Cc1ccccc1

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SLC18A3 Q16572 1/20 0.36
ALOX15 P16050 2/20 0.33
GAA P10253 1/20 0.33
G6PC1 P35575 1/20 0.33
PDE9A O76083 1/20 0.32
CDK1 P06493 1/20 0.32
L3MBTL1 Q9Y468 2/20 0.32
TSHR P16473 1/20 0.32
HTT P42858 1/20 0.32
CTSS P25774 1/20 0.32
CTSK P43235 1/20 0.32
MEN1 O00255 2/20 0.32
KMT2A Q03164 2/20 0.32
ALDH1A1 P00352 1/20 0.32
HSD11B1 P28845 1/20 0.32
NPC1 O15118 1/20 0.31
MAPT P10636 1/20 0.31
RAB9A P51151 1/20 0.31
ABL1 P00519 1/20 0.31
EGFR P00533 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2192073 0.94 SLC18A3 (0.33) SLC18A3TSHRKMT2AALDH1A1
SCHEMBL2196231 0.91 KMT2A (0.36) GAAMEN1KMT2AALDH1A1NPC1
SCHEMBL2197081 0.88 GLA (0.36) TSHRHTTMEN1KMT2AALDH1A1
SCHEMBL2195631 0.88 MEN1 (0.32) MEN1KMT2AALDH1A1NPC1RAB9A
SCHEMBL2198397 0.88 CYP3A4 (0.36) GAACTSSCTSKALDH1A1HSD11B1
SCHEMBL2194640 0.85 CCR3 (0.34) PDE9AALDH1A1HSD11B1
SCHEMBL2195655 0.85 ALDH1A1 (0.32) HTTALDH1A1NPC1RAB9A
SCHEMBL2193570 0.82 SLC6A2 (0.31)
SCHEMBL2197041 0.82 CHRM2 (0.32)
SCHEMBL2196691 0.82 LSS (0.34)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8980875-B2 Platinum-N-heterocyclic carbene derivatives, preparation thereof and therapeutic use thereof CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) 2015-03-17 US claimed
US-20130338128-A1 PLATINUM-N-HETEROCYCLIC CARBENE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) 2013-12-19 US claimed
US-8481522-B2 Platinum-N-heterocyclic carbene derivatives, preparation thereof and therapeutic use thereof SANOFI (FR) 2013-07-09 US claimed
US-20110172199-A1 PLATINUM-N-HETEROCYCLIC CARBENE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF SANOFI-AVENTIS (FR) 2011-07-14 US claimed
US-20110172199-A1 PLATINUM-N-HETEROCYCLIC CARBENE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF SANOFI-AVENTIS (FR) 2011-07-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130338128-A1 PLATINUM-N-HETEROCYCLIC CARBENE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF SCO2, C3AR1, IDH1 SLC18A3 2585/4885ALOX15 1375/4885GAA 4532/4885
US-20110172199-A1 PLATINUM-N-HETEROCYCLIC CARBENE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF SCO2, C3AR1, IDH1 SLC18A3 2585/4885ALOX15 1375/4885GAA 4532/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.